Fw: Lithium and Its Potential Protection from Alzheimer's Disease

Ôò™
Claudia Correa

‚Äã
Fabio Correa;‚Äã
Douglas F. Correa‚Äã
Interesting information about LITHIUM:P  Robert, Dr. Phil and I are researching today! FYI
From: Counselor Claudia Correa Correa 24-25 <claudiac@lahai.org>
Sent: Wednesday, February 4, 2026 4:39 PM
To: Claudia Correa <claudia@headstartcounseling.com>
Subject: Lithium and Its Potential Protection from Alzheimer's Disease
 
Key Articles Connecting Lithium and Dementia

1. Harvard Gazette ‚Äî ‚ÄúAn Alzheimer‚Äôs breakthrough 10 years in the making‚Äù
Main point: Lithium may prevent or even reverse Alzheimer‚Äôs disease, based on new research showing it is a biologically important brain element.
An Alzheimer‚Äôs breakthrough 10 years in the making ‚Äî Harvard Gazette

2. NIH Research Matters ‚Äî ‚ÄúLithium levels tied to Alzheimer‚Äôs disease and dementia‚Äù
Main point:
People with mild cognitive impairment and Alzheimer‚Äôs have significantly reduced lithium levels in the prefrontal cortex.
In mice, low‚Äëdose lithium reversed memory loss and prevented cognitive decline.
Lithium levels tied to Alzheimer‚Äôs disease and dementia | National Institutes of Health (NIH)

3. Harvard‚Äëlinked study ‚Äî ‚ÄúA Low Dose of Lithium May Preserve Cognitive Resilience with Age‚Äù
Main point:
Alzheimer‚Äôs patients show lower brain lithium levels.
In aging adults without Alzheimer‚Äôs, brain lithium correlates with working‚Äëmemory performance.
Low‚Äëdose lithium restored memory in Alzheimer‚Äôs mouse models.
Harvard Study: A Low Dose of Lithium May Preserve Cognitive Resilience with Age

4. Medscape ‚Äî ‚ÄúCan Lithium Orotate Prevent Alzheimer‚Äôs Disease?‚Äù
Main point:
Reviews the claims around lithium orotate and Alzheimer‚Äôs prevention.
Discusses scientific plausibility but emphasizes the need for more evidence.
Can Lithium Orotate Prevent Alzheimer‚Äôs Disease?


5. Psychology Today ‚Äî ‚ÄúCan Lithium Treat Alzheimer‚Äôs Disease?‚Äù
Main point:
Summarizes research suggesting modest doses of lithium may prevent or reverse dementia.
Frames dementia as a major global health burden and highlights lithium‚Äôs potential role.
Can Lithium Treat Alzheimer‚Äôs Disease? | Psychology Today

üß† What These Articles Agree On
Lithium appears to have neuroprotective effects.
Low‚Äëdose lithium is being studied for slowing cognitive decline.
Brain lithium levels may be lower in Alzheimer‚Äôs patients.
Evidence is promising but not yet definitive for clinical recommendations.
‚ö†Ô∏è Important Clinical Note
These findings do not mean people should take lithium supplements to prevent dementia. The research is early, and lithium (even in low doses) can affect kidney and thyroid function. Any use should be discussed with a clinician.

From: Counselor Claudia Correa Correa 24-25 <claudiac@lahai.org>
Sent: Wednesday, February 4, 2026 4:38 PM
To: Phillip Cohen <phillipcohen@comcast.net>; Robert Deeble <Robert@folktowncounseling.com>
Subject: Re: Lithium and Its Potential Protection from Alzheimer's Disease
 
Thank you Dr. Phil,
I just sent you 5 articles I found about this subject. 
From: Phillip Cohen <phillipcohen@comcast.net>
Sent: Wednesday, February 4, 2026 4:33 PM
To: Robert Deeble <Robert@folktowncounseling.com>; Counselor Claudia Correa Correa 24-25 <claudiac@lahai.org>
Subject: Fwd: Lithium and Its Potential Protection from Alzheimer's Disease
 

Sent from my iPhone

Begin forwarded message:

From: Phillip Cohen <phillipcohen@comcast.net>
Date: August 26, 2025 at 9:44:48‚ÄØAM PDT
To: Robert Deeble <robertd@lahai.org>
Subject: Fwd: Lithium and Its Potential Protection from Alzheimer's Disease

Ôªø
Sent from my iPhone

Begin forwarded message:

From: Milton <miljud67@gmail.com>
Date: August 20, 2025 at 8:30:46‚ÄØPM PDT
To: Cohen Phil <phillipcohen@comcast.net>
Subject: Re: Lithium and Its Potential Protection from Alzheimer's Disease

ÔªøI just came across this and have an appointment with my Doc in a couple weeks. I believe the dose was about 5mg. Is that what you used?
There is a question about using it with Losartan so I will see what he thinks.
Milt

On Aug 20, 2025, at 7:32‚ÄØPM, Phillip Cohen <phillipcohen@comcast.net> wrote:

i started Susan on this in the spring of 2023 after consultation with her psychiatrist.  I don‚Äôt think it helped at all because she has mixed type dementia- Alzheimers and vascular.  The data from Scandinavia  about Li and dementia has been known for years but not acknowledged or adopted.  This article is more evidence of possible /probaable efficacy.  The doses with the orotate prep are really, really low.  That doesn‚Äôt mean that it can‚Äôt be effective.  We know from other indications that very low dose Lithium can be helpful eg. in suicide prevention.  One needs normal kidney and thyroid function to take Lithium.  As always consultation with your MDs is important.  Feel fret talk with me about his.  Phil

On Aug 9, 2025, at 1:23‚ÄØPM, Eric Topol from Ground Truths <erictopol+news-and-analyses@substack.com> wrote:


Forwarded this email? Subscribe here for more

Lithium and Its Potential Protection from Alzheimer's Disease
A new, elegant study reawakens the prospects for this metal, and specifically lithium orotate
ERIC TOPOL
AUG 9
 




READ IN APP
 
‚ÄúLithium powers our phones, laptops, and electric vehicles. My guess is the brain might have utilized this unique electrochemistry before we did.‚Äù‚ÄîBruce Yankner, senior author of the new report

If you‚Äôve been reading recent Ground Truths posts, you‚Äôll know I have been focusing on Predicting and Preventing Alzheimer‚Äôs Disease, and the Breakthrough Blood Test for Alzheimer‚Äôs Disease. This week the prospects for reducing the risk of Alzheimer‚Äôs had another advance with a new and impressive study published in Nature by Bruce Yankner and colleagues at Harvard Medical School. In this edition of Ground Truths, I‚Äôll review the key background on Lithium and what we‚Äôve just learned from the new report. I‚Äôll divide this into 3 questions: (1) What Did We Know?; (2) What We Know Now; and (3) What‚Äôs Next?

Share Ground Truths



Subscribed

1. What Did We Know About Lithium and Alzheimer‚Äôs Disease?
Despite lack of knowing its mechanism of action, lithium use for bipolar disorder (BD) and psychiatric conditions dates back to the late 1800‚Äôs and ‚Äîlithium carbonate‚Äî was approved for BD by the FDA in 1970. Its use is associated with a range of serious side effects, including neurologic, kidney and thyroid, establishing it as a medication with a narrow therapeutic window. From 3 different lines of evidence in clinical research, there was support for a potential lithium benefit for relative protection against Alzheimer‚Äôs and dementia (~80% of dementia is Alzheimer‚Äôs) or preservation of cognitive function. 

‚ÄîRandomized Trials
There have been 4 small placebo-controlled randomized trials, 3 of which were included in a meta-analysis, shown below for lithium‚Äôs benefit on cognitive function. Besides being very small (40 to 90 participants), the trials varied for inclusion criteria, length of drug treatment (10 weeks to 15 months), endpoints, levels of blood lithium achieved, and many other factors. The direction was towards benefit for all 3 trials, but only one on its own (Nunes 2013) was statistically significant. 


A more recent randomized, double-blinded, placebo-controlled trial published in 2019, again with a small sample of 61 participants, using lithium carbonate at low doses for 2 years, also supported the finding with less conversion from mild cognitive impairment to dementia by lithium (Figure below, NB: P=0.06 is not significant at the 0.05 level; other measures of cognitive function were statistically significant for lithium‚Äôs advantage). 


Notably, there was an increase in the lithium group concentration of amyloid-Œ≤ in the cerebrospinal fluid vs placebo, suggesting the drug was helping to promote its clearance. 

Another randomized lithium trial at the University of Pittsburgh of 80 participants called LATTICE (Lithium as a Treatment to Prevent Impairment of Cognition in Elders) with 2-year treatment, PET and MRI imaging, has been completed and the results are currently pending.

‚ÄîEvidence in Bipolar Disease
A report from Denmark of nearly 5,000 patients with BD, of whom 30% were treated with lithium, was associated with statistically significant protection from dementia, a link not seen with anticonvulsants, antidepressants, or antipsychotics. (Table below). It has been noted that lithium‚Äôs efficacy is diminished in older people with BPD, which may have something to do with the amyloid sequestration mechanism described below.


‚ÄîEvidence from Drinking Water Exposure
Another nationwide study from Denmark assessed lithium exposure in the water for over 73,000 people who developed dementia and over 730,000 controls. As seen in the Table below, the higher the mean lithium exposure, the more relative protection.


2. What We Know Now
The new paper took an agnostic approach to metals in the human brain, assessing the concentration of 27 of them, and finding only that lithium (Li) stood out in both people with mild cognitive impairment (MCI) and Alzheimer‚Äôs disease (vs individuals no cognitive impairment, NCI). 


Indeed, the concentration of lithium in human brains were markedly different (ratio of cortex to blood or in brain tissue,) as shown below. Notably, the levels of lithium in the brain from people with intact cognition is 1,000X lower than what are achieved with lithium treatment for BD. 


With that background a series of experiments in mice with either lithium deficient diet or lithium repletion were undertaken, in Alzheimer model mice and aged (wild-type) mice, along with the effects of these manipulations on memory, learning, inflammation and related changes in brain cells and tissue.

The principal findings can be summarized:

Amyloid plaque-in the brain binds avidly to lithium and sequesters it(left panel below). That steals the lithium from non-plaque tissue and reduces its function. When the right lithium salt preparation is given (lithium orotate) that doesn‚Äôt get sequestered by amyloid, the microglia cell function is improved to clear amyloid-Œ≤ (right panel below).

A lithium-deficient diet in the Alzheimer model mouse was pro-inflammatory with increased activated microglia (Figure also shown at the top of this post), marked accumulation of amyloid-Œ≤, and phosphorylated tau protein, loss of synapses, axons, myelin, worsened cognitive function and memory.

Finding a lithium salt that was much less likely to form ions and get sequestered by amyloid-Œ≤, turned out to be lithium orotate, markedly better than lithium carbonate, the drug that has been used in BD and that undergone previous clinical trials for cognitive function and progression to Alzheimer‚Äôs disease. 

When compared with lithium carbonate, lithium orotate better prevented accumulation of amyloid-Œ≤, tau-phosphorylation, neuroinfalmmation and cognitive parameter decline. 
Lithium orotate given to aged wild-type mice (not the Alzheimer‚Äôs model mice) reverted their memory to young adult (6-month) level, along with object recognition and maze tasks. 
SIngle-nucleus RNA sequencing showed parallel changes of gene expression between the lithium diet deficient mice and human brain samples with Alzheimer‚Äôs disease. The enzyme glycogen synthase kinase GSK3Œ≤ is activated and expressed by endogenous lithium deficiency. An inhibitor to this kinase may also provide protective effects. 
Subscribed
3. What‚Äôs Next?
The new study is the most impressive neuroscience of lithium published to date. It is comprehensive, mechanistic, and brings together compelling human and mice data (the latter from both the Alzheimer‚Äôs model and aging organism). The work also led to the discovery of a far better lithium salt that reduces the likelihood of being trapped by amyloid-Œ≤, following up the finding that sequestration is foundational to lithium‚Äôs effect. The point that very low doses of lithium would be expected to achieve salutary effects in humans is especially noteworthy, given the toxicity of lithium carbonate at high doses used in BD. Importantly, this extensive work would not have been possible without the support by multiple NIH grants now being subject to profound cuts, no less $2.6 billion specific to Harvard .
The outgrowths of the new study go well beyond reduced brain inflammation and promoting amyloid-Œ≤ clearance to reduce progression to Alzheimer‚Äôs disease, raising the question should lithium levels be assessed as a risk factor and might this also be extended to other neurodegenerative diseases, such as Parkinson‚Äôs. 
Lithium orotate is not naturally found in significant amounts in common foods. Should people start taking lithium orotate, such as the low dose of 5 mg now, widely available as an unregulated supplement? The answer is no, even though we‚Äôd anticipate it would be safe, without worrisome side effects as seen with considerably higher doses of lithium carbonate used for BD. Yes, it‚Äôs tempting, with the body of evidence presented here that exceeds supplements in common use, but we need a clinical trial to prove that the new study translates to a clinical benefit. As I previously discussed with p-tau217 and other blood markers, along with pace of aging brain clocks (using proteomics), it would be straightforward to do a randomized trial and see whether these surrogate metrics are favorably modulated by lithium orotate versus placebo. We hope to initiate such a randomized trial in the near future that would help illuminate whether low dose lithium orotate has efficacy in people.
**************************************************************

Thanks to many of you Ground Truth subscribers who helped put SUPER AGERS on the NYT bestseller list for 4 weeks so far. Here‚Äôs a new video of a fun conversation I had with Dr. Siddhartha Mukherjee on A.I., extending healthspan, and the book. 

I‚Äôm also very appreciative for your reading and subscribing to Ground Truths.

If you found this interesting PLEASE share it!

That makes the work involved in putting these together especially worthwhile.

Share

All content on Ground Truths‚Äîits newsletters, analyses, and podcasts, are free, open-access.

Paid subscriptions are voluntary and all proceeds from them go to support Scripps Research. They do allow for posting comments and questions, which I do my best to respond to. Please don't hesitate to post comments and give me feedback. Let me know topics that you would like to see covered.

Many thanks to those who have contributed‚Äîthey have greatly helped fund our summer internship programs for the past three years. On Friday this week we just had nearly 50 interns (high school, college and medical students) present posters of the work they did over the summer and it was exhilarating!
Invite your friends and earn rewards
If you enjoy Ground Truths, share it with your friends and earn rewards when they subscribe.

Invite Friends
 
LIKE
COMMENT
RESTACK
 
¬© 2025 Eric Topol
548 Market Street PMB 72296, San Francisco, CA 94104 
Unsubscribe
Start writing
